News & Events

June 21, 2023

BrainsWay Announces Significant Expansion in Western and Central U.S.

30 Deep TMS™ Devices Ordered by Large Mental Health-Focused TMS Network    BURLINGTON, Mass. and...

May 23, 2023

BrainsWay Announces Appointment of Ido Marom as CFO

BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

May 17, 2023

BrainsWay Reports First Quarter 2023 Financial Results and Operational Highlights

BURLINGTON, Mass. and JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE:...

May 15, 2023

BrainsWay Launches Investigator Initiated Study (IIS) Program

Application Period Open for Data Collaboration and Equipment Loan Initiatives BURLINGTON, Mass. and JERUSALEM,...

May 3, 2023

BrainsWay to Report First Quarter 2023 Financial Results on May 17, 2023

BURLINGTON, Mass. and JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE:...

May 2, 2023

BrainsWay to Participate in Clinical TMS Society and American Psychiatric Association Meetings

New Research on Deep TMS Depression Treatment to be Presented BURLINGTON, Mass. and JERUSALEM, Israel,...

March 28, 2023

BrainsWay Post-Marketing Study Confirms Substantial Clinical Benefits of Deep TMS™ in Treating Depression and Anxious Depression

BURLINGTON, Mass. and JERUSALEM, March 28, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

March 15, 2023

BrainsWay Reports Fourth Quarter and Full-Year 2022 Financial Results and Operational Highlights

BURLINGTON, Mass. and JERUSALEM, March 15, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

March 2, 2023

BrainsWay Named to Fast Company’s 2023 List of the World’s Most Innovative Companies

BURLINGTON, Mass. and JERUSALEM, March 02, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

March 1, 2023

BrainsWay to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023

BURLINGTON, Mass. and JERUSALEM, Israel, March 01, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ &...

February 23, 2023

BrainsWay Vice President of Medical Affairs Colleen Hanlon Honored with the 2023 International Brain Stimulation Early Career Award

BURLINGTON, Mass. and JERUSALEM, Feb. 23, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

February 13, 2023

BrainsWay Announces Appointment of Hadar Levy as CEO

BURLINGTON, Mass. and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

February 13, 2023

BrainsWay Announces Appointment of Ami Boehm as New Chairman

David Zacut, M.D., Relinquishing Chairman Role Held Since Company’s Inception, to Now Serve as Board...

January 31, 2023

Publication Analyzes Clinical Efficacy of Deep TMS™ in Treating Different Brain Regions Associated with Major Depressive Disorder

Study Results Outline a Potential Path to More Personalized Medicine in Noninvasive Brain Stimulation BURLINGTON,...

January 11, 2023

BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™

BURLINGTON, MA and JERUSALEM, Israel, Jan. 11, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ &...

January 10, 2023

BrainsWay Resolves Neuronetics Litigation

BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

December 13, 2022

BrainsWay Reports Open Market Stock Purchase by Board Member Yossi Ben Shalom

BURLINGTON, Mass. and JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

November 28, 2022

BrainsWay Reports Open Market Stock Purchases by Two Board Members

BURLINGTON, Mass. and JERUSALEM, November 28, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ &...

Find a provider near you or contact us today.

Find a Provider Contact Us